Equip your body to fight off bacterial infections with Rulid
Rulid is part of a group of antibiotics called macrolides. These special types of bacterial fighter work by blocking the proteins that harmful bacteria use to grow and multiply.
Rulid is so powerful that if the bacteria are in enough proliferation, it actually kills the bacteria directly -meaning it’s ‘bactericidal’. Using the body’s defence system of white blood cells, the antibiotics in rulid form in these natural defences. They’re then in the perfect position to be employed in bolstering the immune system.
To treat bacteria infection of the respiratory tract, a Rulid dosage -also known as Rulid -Roxithromycin -is usually prescribed. As well as Rulid -Roxithromycin being used for acute bronchitis, tonsillitis and pneumonia, it’s also used to treat infections of the gastrointestinal tract and the body’s soft tissues.
Antibiotics should only be used when prescribed by your doctor, so it’s important to check to see whether you require them for a certain condition. Side effects are seldom experienced with Rulid and it’s proven itself to be handy weapon to fight off serious infections.
Polioxyethyleneâ€“polioxypropylene co-polymer, polyvinyl pyrrolidone, hydroxypropyl cellulose, precipitate silica, corn starch, magnesium stearate, talc, propylene glycol, anhydrous glucose, methylhydroxypropyl cellulose, titanium dioxide.
Adverse Effects and Precautions:
Gastro-intestinal disturbances are the most frequent adverse effect, but are less frequent than with erythromycin. A case of cholestatic hepatitis has been reported. Rashes, headache, dizziness, weakness and changes in blood cell counts have also occurred. Acute pancreatitis, with duodenal inflammation, pain, pancreatic enlargement and raised serum-amylase developed within 24 hours of substitution of roxithromycin for erythromycin ethyl succinate in a patient being treated for respiratory tract infection. Symptoms resolved rapidly once roxithromycin was withdrawn. Souweine B, et al. Acute pancreatitis associated with roxithromycin therapy. DICP Ann Pharmacother 1991- 25: 1137.
Antimicrobial Action and Resistance:
It is reported to be as active or slightly less active than erythromycin. MICs for the most sensitive strains range from about 0.03 to 1 mcg per ml but organisms with MICs up to about 2 mcg per ml are generally considered sensitive.
Following oral administration roxithromycin is well absorbed, with peak concentrations of about 6 to 8 mcg per ml occurring around 2 hours after a single dose of 150 mg. Absorption is reduced when taken after, but not before, a meal. It is widely distributed in tissues and body fluids. It is reported to be about 96% bound to plasma protein (mainly alpha (1)-acid glycoprotein) at trough concentrations, but binding is saturable, and only about 86% is bound at usual peak concentrations. Small amounts of roxithromycin are metabolized in the liver, and the majority of a dose is excreted in the faeces as unchanged drug and metabolites- about 7 to 12% is excreted in urine, and up to 15% via the lungs. The elimination half-life is reported to range between about 8 and 13 hours, but may be more prolonged in children. References. 1. Puri SK, Lassman HB. Roxithromycin: a pharmacokinetic review of a macrolide. J Antimicrob Chemother 1987- 20 (suppl B): 89-100. 2. Periti P, et al. clinical pharmacokinetic properties of the macrolide antibiotics: effects of age and various pathophysiological states (part II). Clin Pharmacokinet 1989- 16: 261-82.
Uses and Administration:
Roxithromycin is a macrolide antibiotic with actions and uses similar to those of erythromycin. It is given by mouth in a dose of 150 mg twice daily before meals, in the treatment of susceptible infections. 1. Phillips I, et al., (eds). Roxithromycin: a new macrolide. J Antimicrob Chemother 1987- 20 (suppl B): 1-187. 2. Young RA, et al. Roxithromycin: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1989- 37: 8-41. Correction. ibid.,3. Bahal N, Nahata MC. The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin. Ann Pharmacother 1992- 26: 46-55.
Roxithromycin has been reported to be of benefit in patients with late-stage symptoms (neuroborreliosis, (1) arthritis (2)) of Lyme disease, given in combination with co-trimoxazole, although the contribution of the latter is uncertain. (3) 1. Gasser R, Dusleag J. Oral treatment of late borreliosis with roxithromycin plus co-trimoxazole. Lancet 1990- 336: 1189-90. 2. Pedersen LM, Friis-Moller A. Late treatment of chronic Lyme arthritis. Lancet 1991- 337: 241. 3. Bowman CA. Oral treatment of late borreliosis with roxithromycin plus co-trimoxazole. Lancet 1990- 336: 1514.
KEEP OUT OF THE REACH OF CHILDREN
The above information is the translation of the manufacturer’s insert. It is provided under the supplying company’s terms and conditions and should not replace the advice of your personal physician.
MADE IN EU